Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 4 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Stomach Neoplasms 2 Neoplasms 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Peritoneal Neoplasms 1 Pelvic Neoplasms 1 Osteosarcoma 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Appendiceal Neoplasms 1

Interventions

Paclitaxel 95 Carboplatin 77 pembrolizumab 74 Cisplatin 29 Bevacizumab 27 Surveys and Questionnaires 23 Radiotherapy 22 Letrozole 22 Doxorubicin 21 Megestrol Acetate 20 olaparib 19 lenvatinib 19 Taxes 17 Specimen Handling 17 Docetaxel 17 Nivolumab 16 Magnetic Resonance Spectroscopy 16 dostarlimab 15 Metformin 15 Blood Specimen Collection 14 Observation 13 Gemcitabine 13 Biopsy 13 durvalumab 12 Medroxyprogesterone Acetate 12 Trastuzumab 11 Indocyanine Green 11 Fulvestrant 11 temsirolimus 10 abemaciclib 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Endometrial Neoplasms × Pafolacianine × Clear all

NCT07278986 2025-12-12

CYTALUX ISS

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡